138 related articles for article (PubMed ID: 32165081)
1. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
[TBL] [Abstract][Full Text] [Related]
2. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of a new retinoic acid ECPIRM as potential chemotherapeutic agent for human cutaneous squamous carcinoma.
Zhang M; Tao Y; Ma P; Wang D; He C; Cao Y; Wei J; Li L; Tao L
Anticancer Agents Med Chem; 2015; 15(9):1204-12. PubMed ID: 25991427
[TBL] [Abstract][Full Text] [Related]
4. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
5. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
6. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
7. Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells.
Kodigepalli KM; Li M; Liu SL; Wu L
Cell Cycle; 2017 Jan; 16(2):179-188. PubMed ID: 27929746
[TBL] [Abstract][Full Text] [Related]
8. ITK inhibition for the targeted treatment of CTCL.
Bustos-Villalobos I; Bergstrom JW; Haigh NE; Luna JI; Mitra A; Marusina AI; Merleev AA; Wang EA; Sukhov A; Sultani H; Liu R; Bhardwaj G; Guo W; Kung HJ; Lam KS; Maverakis E
J Dermatol Sci; 2017 Jul; 87(1):88-91. PubMed ID: 28434812
[No Abstract] [Full Text] [Related]
9. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
10. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
11. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.
Guo W; Liu R; Ono Y; Ma AH; Martinez A; Sanchez E; Wang Y; Huang W; Mazloom A; Li J; Ning J; Maverakis E; Lam KS; Kung HJ
Mol Pharmacol; 2012 Nov; 82(5):938-47. PubMed ID: 22899868
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.
Wu J; Wood GS
JAMA Dermatol; 2018 Oct; 154(10):1191-1198. PubMed ID: 30167641
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of Neosetophomone B inducing apoptosis in cutaneous T cell lymphoma by targeting the FOXM1 signaling pathway.
Kuttikrishnan S; Masoodi T; Ahmad F; Sher G; Prabhu KS; Mateo JM; Buddenkotte J; El-Elimat T; Oberlies NH; Pearce CJ; Bhat AA; Alali FQ; Steinhoff M; Uddin S
J Dermatol Sci; 2023 Nov; 112(2):83-91. PubMed ID: 37865581
[TBL] [Abstract][Full Text] [Related]
16. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
17. TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.
Zhu M; Yang L; Shi X; Gong Z; Yu R; Zhang D; Zhang Y; Ma W
J Cell Mol Med; 2020 Jan; 24(1):984-995. PubMed ID: 31742861
[TBL] [Abstract][Full Text] [Related]
18. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
[TBL] [Abstract][Full Text] [Related]
19. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
20. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand.
Braun FK; Al-Yacoub N; Plötz M; Möbs M; Sterry W; Eberle J
J Invest Dermatol; 2012 Feb; 132(2):429-39. PubMed ID: 22011910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
